Harmony Biosciences Holdings, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Harmony Biosciences is a commercial-stage pharmaceutical company focused on rare neurological disorders. Its principal commercial product is WAKIX (pitolisant), approved in the United States for excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company also develops pitolisant for additional indications and, following its October 2023 acquisition of Zynerba, is developing ZYN002 for Fragile X Syndrome.
The filing covers the three months ended March 31, 2024, with comparative results for the three months ended March 31, 2023. The interim financial statements are unaudited and prepared under U.S. GAAP.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net product revenue | $154.6 million | $119.1 million | +29.8% |
| Gross profit | $127.1 million | $98.3 million | +29.3% |
| Gross margin | 82.2% | 82.6% | Down 0.4 percentage points |
| Operating income | $52.0 million | $40.4 million | +28.7% |
| Operating margin | 33.7% | 33.9% | Down 0.2 percentage points |
| Net income | $38.3 million | $29.5 million | +30.0% |
| Diluted earnings per share | $0.67 | $0.48 | +39.6% |
| Net cash from operating activities | $31.1 million | $42.6 million | Down $11.4 million |
Revenue growth was driven primarily by a 28.3% increase in units shipped and a January 2024 price increase of approximately 7%, partially offset by higher commercial rebates that reduced revenue by approximately 4%. Cost of product sales increased 32.3% to $27.5 million, resulting in modest gross-margin compression.
Operating expenses increased 29.7% to $75.1 million. Research and development expense rose 67.0% to $22.2 million, primarily due to ZYN002 development, higher pitolisant clinical and regulatory activity, increased personnel costs, and stock-based compensation. Sales and marketing expense increased 20.6% to $27.2 million, while general and administrative expense increased 16.4% to $25.7 million, including higher stock-based compensation and legal fees.
Interest expense declined to $4.5 million from $5.7 million, primarily following refinancing into the Term Loan A facility. Interest income increased to $4.4 million from $3.1 million due to higher invested balances and yields. The effective tax rate increased to 26.0% from 22.0%.
Balance sheet, liquidity and debt
- Cash and cash equivalents were $333.0 million at March 31, 2024, compared with $311.7 million at December 31, 2023.
- Total investments were $120.6 million, comprising $39.4 million of short-term investments and $81.2 million of long-term investments.
- Cash, cash equivalents and investments totaled $453.6 million.
- Total debt principal was $192.5 million, net debt on the balance sheet was $190.0 million, and the fair value of the Term Loans was $192.3 million.
- The Term Loans require quarterly principal payments of approximately $3.75 million through 2025, increasing to $5.0 million beginning in late 2025, with a $115.0 million payment due at maturity on July 26, 2028.
- Net cash increased by $21.3 million during the quarter to $333.3 million, including restricted cash.
- Management believes existing cash, investments and expected cash generation will fund operational liquidity needs and planned investing activities for at least the next 12 months.
- The company was in compliance with its debt covenants as of March 31, 2024.
Material changes versus the prior comparable period
- WAKIX revenue increased $35.5 million, or 29.8%, reflecting higher shipment volume and pricing.
- Research and development expense increased $8.9 million, including $3.9 million related to ZYN002, which had no comparable prior-year expense.
- Operating cash flow decreased $11.4 million, primarily because of working-capital movements, including higher receivables and changes in liabilities.
- Weighted-average basic shares declined to 56.8 million from 59.7 million, while diluted EPS increased to $0.67 from $0.48.
- No shares were repurchased during the quarter. The October 2023 repurchase program had $150.0 million remaining authorization at March 31, 2024.
- Stock-based compensation expense increased to approximately $10.4 million from $6.6 million.
Guidance, outlook, commentary and unusual items
- The filing does not provide clear numerical full-year revenue, earnings or cash-flow guidance.
- The company submitted or expects to submit an sNDA for idiopathic hypersomnia in the second half of 2024, despite the INTUNE Phase 3 trial’s primary endpoint not reaching statistical significance. Management is relying on the totality of the available data and reported a March 2024 FDA meeting regarding the path forward.
- The Phase 3 TEMPO study of pitolisant in Prader-Willi Syndrome began in March 2024. The pediatric narcolepsy sNDA received priority review, with an FDA target action date of June 21, 2024.
- Topline data from Zynerba’s Phase 3 RECONNECT study of ZYN002 in Fragile X Syndrome is anticipated in mid-2025.
- The company expects continued elevated research and development spending as it advances pitolisant programs, ZYN002, HBS-102 and additional formulations of pitolisant.
- In April 2024, the company entered a sublicense for a preclinical orexin-2 receptor agonist. It paid a $25.5 million upfront fee and may owe up to $127.5 million in development and regulatory milestones, $240.0 million in sales milestones, and mid-teens royalties on sales.
- On April 30, 2024, Zynerba acquired Epygenix for $35.0 million upfront, subject to adjustment, with potential development and regulatory milestones of up to $130.0 million and sales milestones of up to $515.0 million.
- WAKIX supply was described as adequate to cover demand into the third quarter of 2025, with additional active pharmaceutical ingredient inventory supporting at least 36 additional months.
- Multiple generic-drug manufacturers have filed ANDAs challenging WAKIX patents. The related patent cases were consolidated, with claim-construction hearings scheduled for March 2025 and a bench trial beginning in February 2026.
Principal risks and contingencies
- Revenue and receivables are highly concentrated: three specialty-pharmacy customers accounted for 100% of Q1 product revenue and gross accounts receivable.
- The company depends on a single supplier for WAKIX and a single supplier for its active pharmaceutical ingredient.
- Generic competition and ongoing ANDA patent litigation could affect the duration and economics of WAKIX exclusivity.
- Pipeline programs depend on successful clinical results, regulatory approvals, commercial acceptance, reimbursement and adequate financing.
- Clinical development costs and timelines remain uncertain, particularly for ZYN002, pitolisant expansion indications and HBS-102.
- Future contingent consideration and milestone obligations related to Zynerba, Epygenix, the orexin-2 receptor agonist and existing license agreements could be material.
- The company reported no material outstanding claims or suits other than the disclosed patent litigation and stated that its disclosure controls were effective as of March 31, 2024.
Investor verification checklist
- Verify the sustainability of WAKIX volume growth, pricing, rebates, gross margin and specialty-pharmacy concentration.
- Track the June 21, 2024 FDA action on the pediatric narcolepsy sNDA and the planned idiopathic hypersomnia sNDA.
- Assess clinical and regulatory progress for the TEMPO, RECONNECT, HBS-102 and next-generation pitolisant programs.
- Review the outcome and timing of the WAKIX ANDA patent litigation and the potential effect on exclusivity through the disclosed patent expiration dates.
- Monitor operating cash conversion, working-capital requirements, debt amortization and the $115.0 million 2028 maturity payment.
- Quantify potential milestone, royalty and contingent-value-right obligations from the company’s licensing and acquisition activities.